secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152834
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon increases inducement equity plan share reserve from 900k to 1.175M shares
-------------------------------------------------------------------------------

- Amended 2025 Inducement Plan to raise maximum shares reserved from 900,000 to 1,175,000, a 30.6% increase.
- Shares are reserved exclusively for inducement grants (nonstatutory options, RSUs, etc.) to new employees.
- Amendment approved by independent directors; shareholder approval not obtained per Nasdaq Rule 5635(c)(4).
- Plan amended effective April 7, 2026; full text filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526152834/0001193125-26-152834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526152834/xene-20260407.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer